An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: The University of Texas MD Anderson Cancer Center, Sarah Cannon, Tennessee Oncology, Fox Chase Cancer Center, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, University of Alabama at Birmingham, Deciphera Pharmaceuticals (United States), The Ohio State University Wexner Medical Center
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3028719099